Interaction between activated VD3 and Ca channel blockers in patients undergoing hemodialysis.
Negoro
S
S
Izumi
S
S
Furukubo
T
T
Satoh
M
M
Matsunaga
C
C
Yamakawa
T
T
Ikegawa
S
S
Nakanishi
H
H
Kadowaki
D
D
Hirata
S
S
D017311:Amlodipine / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002117:Calcitriol / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D009543:Nifedipine / Q000627:therapeutic use; D006435:Renal Dialysis
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D006887:Hydroxycholecalciferols; D017311:Amlodipine; D003577:Cytochrome P-450 Enzyme System; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D002117:Calcitriol; D009543:Nifedipine; C008088:alfacalcidol